Analysts believe Johnson & Johnson (NYSE:JNJ) is worth $124.56 per share
- Author: Zachary Reyes Feb 16, 2017,
Feb 16, 2017, 17:19
Earnings per share (ttm) for Johnson & Johnson (NYSE:JNJ) according to Finviz Data is $5.94.
U.S. Bancorp (NYSE:USB) went up 0.97% during trading on the US exchange when it had traded 5.7M shares. Johnson & Johnson comprises approximately 1.1% of Morgan Dempsey Capital Management LLC's portfolio, making the stock its 27th largest position.
Other hedge funds have also added to or reduced their stakes in the company. Shelton Capital Management raised its stake in shares of Johnson & Johnson by 17.5% in the second quarter. Lenox Wealth Management Inc. raised its position in shares of Johnson & Johnson by 24.3% in the second quarter. The firm owned 13,270 shares of the company's stock after buying an additional 647 shares during the period. Gardiner Nancy B raised its position in shares of Johnson & Johnson by 61.7% in the third quarter. Fundsmith LLP now owns 3,704,693 shares of the company's stock worth $449,379,000 after buying an additional 719,532 shares in the last quarter. Dempze Nancy E raised its position in shares of Johnson & Johnson by 0.4% in the third quarter. Putnam FL Investment Management Co. now owns 40,875 shares of the company's stock worth $4,829,000 after buying an additional 27,850 shares in the last quarter. Finally, Diker Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth about $206,000. The fund owned 80,114 shares of the company's stock after selling 2,060 shares during the period.
Johnson & Johnson (NYSE:JNJ) rose 0.41% or 0.48 points on Tuesday and made its way into the gainers of the day. Stock's intraday price range hit the peak level of $116.40 and touched the lowest level of $115.32. The company has a market cap of $315.26 billion, a P/E ratio of 19.54 and a beta of 0.74.
The stock as of last trading session moved 19.18% up from its 52 week low and was -6.83% behind its 52 week high.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 24th. Stock analysts expect it to report per-share earnings of $1.76 in that period. The company earned $18.10 billion during the quarter, compared to analysts' expectations of $18.28 billion. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%.
The company announced its last quarter financial performance results on 01/24/2017. During the same quarter in the previous year, the company posted $1.44 EPS. Analysts predict that Johnson & Johnson will post $7.04 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 14th.
Company has reported several Insider transactions to the SEC, on Feb 3, 2017, Michael H Ullmann (Exec VP, General Counsel) sold 21,735 shares at 112.88 per share price.On Jul 28, 2016, Dominic J Caruso (Exec VP, Finance; CFO) sold 41,146 shares at 125.01 per share price.On Jul 25, 2016, Ronald A Kapusta (Controller, CAO) sold 2,935 shares at 125.01 per share price. The ex-dividend date of this dividend is Friday, February 24th.
Bioverativ Inc. (NASDAQ:BIVV) kept active in profitability ratio analysis, on current situation shares price raised 0.32% to $44.51. If you are accessing this piece on another site, it was illegally copied and republished in violation of United States and global copyright and trademark law. The original version of this news story can be accessed at https://www.com-unik.info/2017/02/15/whalerock-point-partners-llc-invests-5965000-in-johnson-johnson-jnj.html.
One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the stock.
Johnson & Johnson (NYSE:JNJ) has received a short term rating of hold from experts at Zacks with a rank of 3. Finally, Bank of America Corporation reaffirmed a "hold" rating and issued a $126.00 target price on shares of Johnson & Johnson in a research note on Monday, November 28th. The most recent downgrade was reported by Wells Fargo on Jan 26, 2017, with a rating change from Outperform to Market Perform. Argus reissued a "buy" rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 21st. (The) cut their price objective on Johnson & Johnson from $120.00 to $115.00 and set a "neutral" rating for the company in a report on Wednesday, January 25th.